資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34681
|
| 標題: | Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma |
| 作者: | Kuo, Hsin-Yu
Han, Meng-Zhi
Liao, Chih-Hsiang
Lin, Yih-Jyh
Wang, Chung-Teng
Chen, Shang-Hung
Chang, Ting-Tsung
Chen, Po-Jun
Lin, Sheng-Hsiang
Chen, Chiung-Yu
Chuang, Chiao-Hsiung
Wu, I-Chin
Wu, Juei-Seng
Hong, Tzu-Chun
Hsieh, Ming-Tsung
Lee, Yang-Cheng
Wu, Hung-Tsung
Tsai, Hong-Ming |
| 貢獻者: | National Cheng Kung University
National Cheng Kung University Hospital
National Cheng Kung University
China Medical University Taiwan
Chia Nan University of Pharmacy & Science
National Cheng Kung University
National Cheng Kung University Hospital
National Cheng Kung University
National Cheng Kung University Hospital
National Health Research Institutes - Taiwan
National Cheng Kung University
National Cheng Kung University
National Cheng Kung University Hospital
National Cheng Kung University
National Cheng Kung University
National Cheng Kung University Hospital |
| 關鍵字: | checkpoint inhibitors
therapy |
| 日期: | 2022 |
| 上傳時間: | 2023-12-11 14:04:53 (UTC+8) |
| 出版者: | MDPI |
| 摘要: | Purpose: Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile for these drugs are still scarce. Thus, the aims of this study were to investigate the differences in efficacy and safety between nivolumab and pembrolizumab in unresectable HCC patients in a real-world setting. Patients and methods: A total of 115 patients who received treatment with nivolumab (n = 73) or pembrolizumab (n = 42) in combination with or without tyrosine kinase inhibitors was enrolled. Therapeutic response, survival outcomes, and safety profiles were compared among these groups. Multivariate analysis of survival response was performed using Cox proportional hazards regression. Results: Patients treated with pembrolizumab demonstrated a significantly higher objective response rate than those with nivolumab (38.1% vs. 15.1%; odds ratio 4.18, p = 0.005) regardless of the combination strategies. In addition, pembrolizumab performed a better overall survival (OS) than nivolumab, (34.9 vs. 9.5 months; hazard ratio (HR) = 0.39, p = 0.004). In subgroup analysis, pembrolizumab exhibited favorable OS than nivolumab for monotherapy (HR = 0.16, p = 0.001) or combination therapy (HR = 0.33, p = 0.006) as second-line or later-line (HR = 0.19, p = 0.001) therapy and those with (HR = 0.31, p = 0.006) or without (HR = 0.15, p = 0.004) well-compensated liver disease. The incidence of adverse events was comparable for both treatments. Conclusion: Both pembrolizumab and nivolumab had significant effects for HCC therapy, and pembrolizumab had a significant survival benefit as compared with nivolumab. |
| 關聯: | PHARMACEUTICS, v.14, n.CB2, pp.CC2, pp.-, |
| 顯示於類別: | [行政單位] 123
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 54 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
